Palbociclib Pfizer

Menu

Close

HomeAboutMode of actionEfficacyPALOMA-2Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)PALOMA-3Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)Real World EvidenceP-REALITY study designP-REALITY patients characteristicsP-REALITY real-world progression-free survivalP-REALITY overall survivalP-REALITY strengthsSafetyImportant Safety InformationSafetySafety overviewPooled ARsPooled laboratory abnormalitiesPALOMA-2 AEsPALOMA-3 AEsSelected safety featuresPalbociclib long-term safetyGI and liver toxicitiesEffect of Palbociclib on QTc intervalElderly patientsVisceral disease patientsDose reduction effect on efficacyDosingRecommended dosing scheduleRecommended dose modifications for AEsOne scheduled monitoring provisionMedical InformationVisit the Pfizer Medical Information Africa Website for Healthcare ProfessionalsSubmit a medical question to Pfizer

To report an adverse event, please contact [email protected]
PALOMA-3 progression-free survival

In PALOMA-3, Palbociclib Pfizer in combination with fulvestrant in 1st line or later doubled mPFS vs placebo + fulvestrant in patients with progression on/after ET*1,2

PALOMA-3 PFS* Kaplan-Meier Curve1,2

In a 2:1 randomised, double-blind, Phase III trial of women with HR+/HER2- mBC whose disease progressed following ET (N=521)2

Adapted from Cristofanilli M, et al. 20162 and Palbociclib Pfizer SmPC.1​​​​​​Evaluated according to RECIST Version1.1.2Data cut-off date: March 16, 2015.
Updated non-prespecified analysis. Data cut-off date: October 23, 2015.

Palbociclib Pfizer in combination with fulvestrant reduced the risk of disease progression vs placebo+fulvestrant in multiple pre-defined patient subpopulations2,3

Subpopulations included:
  •  
  • Pre-/peri-menopausal women
  • Elderly patients (≥65 years)
  • Patients with visceral metastases
  •  
PALOMA-3 PFS Subgroup Analyses2,3 Download chart Adapted from Palbociclib Pfizer EPAR Public assessment report.3
Data cut-off: 23 October 2015.
*Visceral metastasis was defined as lung, liver, brain, pleural, or peritoneal involvement.2 Sensitivity to prior hormonal therapy is defined as either a) documented clinical benefit (i.e. complete response, partial response or stable disease ≥24 weeks) to at least 1 prior hormonal therapy in the metastatic setting or b) at least 24 months of adjuvant hormonal therapy prior to recurrence.3 Disease-free interval is time from diagnosis of primary breast cancer to first relapse in patients who received adjuvant therapy.3 Aromatase inhibitor = anastrazole, letrozole or exemestane. 
Anti-estrogen = tamoxifen, tamoxifen citrate, toremifene, or toremifene citrate. 
Other = neither an aromatase inhibitor nor an anti-estrogen.*Evaluated according to RECIST Version 1.1.¹Explore More PALOMA-2

See PALOMA-2 progression-free survival data

 Learn more Expert opinion

What do experts think about the efficacy of IBRANCE?
​​​​​​​Expert opinion (Placeholder for local video content)

 Learn more
Cl = confidence interval; ECOG = Eastern Oncology Cooperative Group; ET= endocrine therapy; FUL = fulvestrant; HR = hazard ratio; ITT = intention to treat; HR+/HER2- = hormone receptor-positive, human epidermal growth factor receptor 2-negative; mBC = metastatic breast cancer; mPFS = median progression-free survival; n = number of patients; PFS = progression-free survival; PLA = placebo; RECIST = Response Evaluation Criteria in Solid Tumors; SmPC = Summary of Product Characteristics.References:Palbociclib Pfizer Summary of Product Characteristics.Cristofanilli M, et al. Lancet Oncol. 2016;17(4):425-439.
Palbociclib Pfizer EPAR Public assessment report. 25 Nov 2016. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003853/WC500217198.pdf. Accessed March 2022.
PALOMA-3 IBRANCE in the real-world setting Discover how patients responded to IBRANCE combination therapy in the real-world setting
 Find out more

A broad range of patients with HR+/HER2- mBC are eligible for Palbociclib Pfizer + letrozole combination therapy

 See patient profiles

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

This site is intended only for Rwanda health care professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2022 Pfizer Inc. All rights reserved.

Disclaimer: The product is not yet licensed by the Board of Health of Rwanda (Rwanda FDA). The product has however obtained prior Board of Health approval for supply to Accord program channels in Rwanda.

You are now leaving Accord Portal to access Pfizer Medical Information Portal  You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.